Molecular docking studies and structural&electronic analysis of gefarnate

ArticleAçık Erişim

Özet

This study focused on the structural/electronic features of an anti-ulcer agent, gefarnate. The molecular geometry of the compound was calculated using Gaussian 09 W software and the structure was optimized using the DFT/B3LYP method with the 6–31++G(d,p) basis set ground state. Also, in silico studies like molecular docking studies and ADME/T estimation were carried out using web-based tools and software. The protein used in these calculations is the crystal structure of the 3U6J, VEGFR2 kinase domain in complex with a pyrazolone inhibitor. The binding energy for the gefarnate molecule-VEGFR2 kinase complex has been computed as −8.6 kcal/mol. The compound showed no toxicity properties including cytotoxic, mutagenic, carcinogenic, or immunogenic. © 2023 Indian Chemical Society

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/12267Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1016/j.jics.2023.100971Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorÇağlar Yavuz, Sevtap
dc.date.accessioned2026-10-18T20:27:11.196399313Z
dc.date.available2026-10-18T20:27:11.196399313Z
dc.date.issued2023
dc.description.abstractThis study focused on the structural/electronic features of an anti-ulcer agent, gefarnate. The molecular geometry of the compound was calculated using Gaussian 09 W software and the structure was optimized using the DFT/B3LYP method with the 6–31++G(d,p) basis set ground state. Also, in silico studies like molecular docking studies and ADME/T estimation were carried out using web-based tools and software. The protein used in these calculations is the crystal structure of the 3U6J, VEGFR2 kinase domain in complex with a pyrazolone inhibitor. The binding energy for the gefarnate molecule-VEGFR2 kinase complex has been computed as −8.6 kcal/mol. The compound showed no toxicity properties including cytotoxic, mutagenic, carcinogenic, or immunogenic. © 2023 Indian Chemical Society
dc.identifier.doi10.1016/j.jics.2023.100971
dc.identifier.issn0019-4522
dc.identifier.issue4
dc.identifier.scopus2-s2.0-85150387927
dc.identifier.startpage100971
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/12267
dc.identifier.volume100
dc.identifier.wosWOS:000961653100001
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofJournal of the Indian Chemical Society
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectADMET
dc.subjectDFT
dc.subjectGefarnate
dc.subjectMolecular docking
dc.subjectacetylsalicylic acid
dc.subjectcelecoxib
dc.subjectcyclooxygenase 2 inhibitor
dc.subjectcytochrome P450 1A2 inhibitor
dc.subjectcytochrome P450 2C19 inhibitor
dc.subjectcytochrome P450 2C9 inhibitor
dc.subjectcytochrome P450 2D6 inhibitor
dc.subjectdiclofenac
dc.subjectdiflunisal
dc.subjectetodolac
dc.subjectetoricoxib
dc.subjectfenoprofen calcium
dc.subjectibuprofen
dc.subjectindometacin
dc.subjectketoprofen
dc.subjectlumiracoxib
dc.subjectmagnesium salicylate
dc.subjectmefenamic acid
dc.subjectnaproxen
dc.subjectphosphotransferase
dc.subjectpiroxicam
dc.subjectpyrazolone
dc.subjectsalsalate
dc.subjectvasculotropin receptor 2
dc.subjectArticle
dc.subjectcalculation
dc.titleMolecular docking studies and structural&electronic analysis of gefarnate
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus1
rdl.citation.wos0
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)